Network pharmacology analysis of the anti-cancer pharmacological mechanisms of Ganoderma lucidum extract with experimental support using Hepa1-6-bearing C57 BL/6 mice

Journal of Ethnopharmacology

Volumn 210, Issue , 2018, Pages 287-295

  Zhao, Ruo lin ^a   He, Yu min ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cancer; Ganoderma lucidum; Network pharmacology; Target gene

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERGOSTEROL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GANODERENIC ACID A; GANODERENIC ACID D; GANODERENIC ACID G; GANODERIC ACID A; GANODERIC ACID B; GANODERIC ACID C2; GANODERIC ACID D; GANODERIC ACID H; GANODERIC ACID Y; GANODERMA LUCIDUM EXTRACT; GENISTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN RECEPTOR; KAEMFEROL; MITOGEN ACTIVATED PROTEIN KINASE 1; MULTIDRUG RESISTANCE PROTEIN 1; MUSCARINIC M2 RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR MARKER; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; ELECTROSPRAY MASS SPECTROMETRY; GANODERMA; GANODERMA LUCIDUM; GANODERMA SINENSE; GENE TARGETING; HEPA 1-6 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PREDICTION; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; UPREGULATION; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; ISOLATION AND PURIFICATION; LIVER TUMOR; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOWN-REGULATION; GANODERMA; GENE EXPRESSION REGULATION, NEOPLASTIC; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR DOCKING SIMULATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 85028938003     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2017.08.041     Document Type: Article

References (45)

1. Allemani, C., Weir, H.K., Carreira, H., Harewood, R., Spika, D., Wang, X.S., Bannon, F., Ahn, J.V., Johnson, C.J., Bonaventure, A., Marcos-Gragera, R., Stiller, C., Azevedo e Silva, G., Chen, W.Q., Ogunbiyi, O.J., Rachet, B., Soeberg, M.J., You, H., Matsuda, T., Bielska-Lasota, M., Storm, H., Tucker, T.C., Coleman, M.P., Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385:9972 (2015), 977–1010.
2. Carracedo, A., Lorente, M., Egia, A., Blazquez, C., Garcia, S., Giroux, V., Malicet, C., Villuendas, R., Gironella, M., Gonzalez-Feria, L., Piris, M.A., Iovanna, J.L., Guzman, M., Velasco, G., The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9:4 (2006), 301–312.
3. Cheng, S., Sliva, D., Ganoderma lucidum for cancer treatment: we are close but still not there. Integr. Cancer Ther. 14:3 (2015), 249–257.
4. Fitzmaurice, C., Allen, C., Barber, R.M., Barregard, L., Bhutta, Z.A., Brenner, H., Dicker, D.J., Chimed-Orchir, O., Dandona, R., Dandona, L., Fleming, T., Forouzanfar, M.H., Hancock, J., Hay, R.J., Hunter-Merrill, R., Huynh, C., Hosgood, H.D., Johnson, C.O., Jonas, J.B., Khubchandani, J., Kumar, G.A., Kutz, M., Lan, Q., Larson, H.J., Liang, X., Lim, S.S., Lopez, A.D., MacIntyre, M.F., Marczak, L., Marquez, N., Mokdad, A.H., Pinho, C., Pourmalek, F., Salomon, J.A., Sanabria, J.R., Sandar, L., Sartorius, B., Schwartz, S.M., Shackelford, K.A., Shibuya, K., Stanaway, J., Steiner, C., Sun, J., Takahashi, K., Vollset, S.E., Vos, T., Wagner, J.A., Wang, H., Westerman, R., Zeeb, H., Zoeckler, L., Abd-Allah, F., Ahmed, M.B., Alabed, S., Alam, N.K., Aldhahri, S.F., Alem, G., Alemayohu, M.A., Ali, R., Al-Raddadi, R., Amare, A., Amoako, Y., Artaman, A., Asayesh, H., Atnafu, N., Awasthi, A., Saleem, H.B., Barac, A., Bedi, N., Bensenor, I., Berhane, A., Bernabe, E., Betsu, B., Binagwaho, A., Boneya, D., Campos-Nonato, I., Castaneda-Orjuela, C., Catala-Lopez, F., Chiang, P., Chibueze, C., Chitheer, A., Choi, J.Y., Cowie, B., Damtew, S., das Neves, J., Dey, S., Dharmaratne, S., Dhillon, P., Ding, E., Driscoll, T., Ekwueme, D., Endries, A.Y., Farvid, M., Farzadfar, F., Fernandes, J., Fischer, F., TT, G.H., Gebru, A., Gopalani, S., Hailu, A., Horino, M., Horita, N., Husseini, A., Huybrechts, I., Inoue, M., Islami, F., Jakovljevic, M., James, S., Javanbakht, M., Jee, S.H., Kasaeian, A., Kedir, M.S., Khader, Y.S., Khang, Y.H., Kim, D., Leigh, J., Linn, S., Lunevicius, R., El Razek, H.M.A., Malekzadeh, R., Malta, D.C., Marcenes, W., Markos, D., Melaku, Y.A., Meles, K.G., Mendoza, W., Mengiste, D.T., Meretoja, T.J., Miller, T.R., Mohammad, K.A., Mohammadi, A., Mohammed, S., Moradi-Lakeh, M., Nagel, G., Nand, D., Le Nguyen, Q., Nolte, S., Ogbo, F.A., Oladimeji, K.E., Oren, E., Pa, M., Park, E.K., Pereira, D.M., Plass, D., Qorbani, M., Radfar, A., Rafay, A., Rahman, M., Rana, S.M., Soreide, K., Satpathy, M., Sawhney, M., Sepanlou, S.G., Shaikh, M.A., She, J., Shiue, I., Shore, H.R., Shrime, M.G., So, S., Soneji, S., Stathopoulou, V., Stroumpoulis, K., Sufiyan, M.B., Sykes, B.L., Tabares-Seisdedos, R., Tadese, F., Tedla, B.A., Tessema, G.A., Thakur, J.S., Tran, B.X., Ukwaja, K.N., Uzochukwu, B.S.C., Vlassov, V.V., Weiderpass, E., Wubshet Terefe, M., Yebyo, H.G., Yimam, H.H., Yonemoto, N., Younis, M.Z., Yu, C., Zaidi, Z., Zaki, M.E.S., Zenebe, Z.M., Murray, C.J.L., Naghavi, M., Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990–2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 3 (2017), 524–548.
5. Gill, B.S., Kumar, S., Navgeet, Triterpenes in cancer: significance and their influence. Mol. Biol. Rep. 43:9 (2016), 881–896.
6. Gordaliza, M., Natural products as leads to anticancer drugs. Clin. Transl. Oncol. 9:12 (2007), 767–776.
7. Grindstad, T., Andersen, S., Al-Saad, S., Donnem, T., Kiselev, Y., Nordahl Melbo-Jorgensen, C., Skjefstad, K., Busund, L.-T., Bremnes, R.M., Richardsen, E., High progesterone receptor expression in prostate cancer is associated with clinical failure. PLoS One, 10(2), 2015, e0116691.
8. Huang da, W., Sherman, B.T., Lempicki, R.A., Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1 (2009), 1–13.
9. Huang da, W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4:1 (2009), 44–57.
10. Huang, W.-C., Chen, C.-L., Lin, Y.-S., Lin, C.-F., Apoptotic sphingolipid ceramide in cancer therapy. J. Lipids, 2011, 2011, 565316.
11. Huie, C.W., Di, X., Chromatographic and electrophoretic methods for Lingzhi pharmacologically active components. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 812:1–2 (2004), 241–257.
12. Hyde, Z., Flicker, L., McCaul, K.A., Almeida, O.P., Hankey, G.J., Chubb, S.A.P., Yeap, B.B., Associations between testosterone levels and incident prostate, lung, and colorectal cancer. A population-based study. Cancer Epidemiol. Biomark. Prev. 21:8 (2012), 1319–1329.
13. Khazir, J., Riley, D.L., Pilcher, L.A., De-Maayer, P., Mir, B.A., Anticancer agents from diverse natural sources. Nat. Prod. Commun. 9:11 (2014), 1655–1669.
14. Lee, C.K., Yang, Y., Chen, C., Liu, J., Syk-mediated tyrosine phosphorylation of mule promotes TNF-induced JNK activation and cell death. Oncogene 35:15 (2016), 1988–1995.
15. Li, S., Network target: a starting point for traditional Chinese medicine network pharmacology. Zhongguo Zhong Yao Za Zhi 36:15 (2011), 2017–2020.
16. Lv, Y.N., Li, S.X., Zhai, K.F., Kou, J.P., Yu, B.Y., Network pharmacology-based prediction and verification of the molecular targets and pathways for schisandrin against cerebrovascular disease. Chin. J. Nat. Med. 12:4 (2014), 251–258.
17. Ma, W.-L., Hsu, C.-L., Yeh, C.-C., Wu, M.-H., Huang, C.-K., Jeng, L.-B., Hung, Y.-C., Lin, T.-Y., Yeh, S., Chang, C., Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology 56:1 (2012), 176–185.
18. Marquez-Garban, D.C., Chen, H.-W., Fishbein, M.C., Goodglick, L., Pietras, R.J., Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 72:2 (2007), 135–143.
19. Mueller, K.M., Themanns, M., Friedbichler, K., Kornfeld, J.-W., Esterbauer, H., Tuckermann, J.P., Moriggl, R., Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development. Mol. Cell Endocrinol. 361:1–2 (2012), 1–11.
20. Nie, H., Li, J., Yang, X.-M., Cao, Q.-Z., Feng, M.-X., Xue, F., Wei, L., Qin, W., Gu, J., Xia, Q., Zhang, Z.-G., Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma. Hepatology 62:4 (2015), 1145–1159.
21. Pei, L., Bao, Y., Liu, S., Zheng, J., Chen, X., Material basis of Chinese herbal formulas explored by combining pharmacokinetics with network pharmacology. PLoS One, 8(2), 2013, e57414.
22. Peters, K.M., Edwards, S.L., Nair, S.S., French, J.D., Bailey, P.J., Salkield, K., Stein, S., Wagner, S., Francis, G.D., Clark, S.J., Brown, M.A., Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events. BMC Cancer, 12, 2012, 132.
23. Prat, A., Cheang, M.C.U., Martin, M., Parker, J.S., Carrasco, E., Caballero, R., Tyldesley, S., Gelmon, K., Bernard, P.S., Nielsen, T.O., Perou, C.M., Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J. Clin. Oncol. 31:2 (2013), 203–209.
24. Ruan, W., Wei, Y., Popovich, D.G., Distinct responses of cytotoxic ganoderma lucidum triterpenoids in human carcinoma cells. Phytother. Res. 29:11 (2015), 1744–1752.
25. Safavi, S., Hansson, M., Karlsson, K., Biloglav, A., Johansson, B., Paulsson, K., Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia. Haematologica 100:1 (2015), 55–61.
26. Saranga Bharathi, R., Singh, R., Gupta, R., Verma, G.R., Kalra, N., Kiran, K., Joshi, K., Female sex hormone receptors in gallbladder cancer. J. Gastrointest. Cancer 46:2 (2015), 143–148.
27. Schwarz, J.K., Payton, J.E., Rashmi, R., Xiang, T., Jia, Y., Huettner, P., Rogers, B.E., Yang, Q., Watson, M., Rader, J.S., Grigsby, P.W., Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin. Cancer Res. 18:5 (2012), 1464–1471.
28. Sheng, S., Wang, J., Wang, L., Liu, H., Li, P., Liu, M., Long, C., Xie, C., Xie, X., Su, W., Network pharmacology analyses of the antithrombotic pharmacological mechanism of Fufang Xueshuantong Capsule with experimental support using disseminated intravascular coagulation rats. J. Ethnopharmacol. 154:3 (2014), 735–744.
29. Sheppard, K., Kinross, K.M., Solomon, B., Pearson, R.B., Phillips, W.A., Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit. Rev. Oncog. 17:1 (2012), 69–95.
30. Shi, L., Lin, H., Li, G., Jin, R.-A., Xu, J., Sun, Y., Ma, W.-L., Yeh, S., Cai, X., Chang, C., Targeting androgen receptor (AR)IL12A signal enhances efficacy of sorafenib plus NK cells immunotherapy to better suppress HCC progression. Mol. Cancer Ther. 15:4 (2016), 731–742.
31. Siegel, R.L., Miller, K.D., Jemal, A., Cancer Statistics, 2017. CA: Cancer J. Clin. 67:1 (2017), 7–30.
32. Spindel, E.R., Muscarinic receptor agonists and antagonists: effects on cancer. Handb. Exp. Pharmacol.(208), 2012, 451–468.
33. Tan, F., Thiele, C.J., Li, Z., Neurotrophin signaling in cancer. Kostrzewa, R.M., (eds.) Handbook of Neurotoxicity, 2014, Springer New York, New York, NY, 1825–1847.
34. Vonlanthen, J., Okoniewski, M.J., Menigatti, M., Cattaneo, E., Pellegrini-Ochsner, D., Haider, R., Jiricny, J., Staiano, T., Buffoli, F., Marra, G., A comprehensive look at transcription factor gene expression changes in colorectal adenomas. BMC Cancer, 14, 2014, 46.
35. Wang, C.J., Guo, D.K., You, T.G., Shen, D.W., Wang, C., Tang, L., Wang, J., Xu, R.H., Zhang, H., Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor alpha and Wnt pathways in vitro and in patients. Mol. Med. Rep. 10:6 (2014), 3125–3131.
36. Wang, X., Xu, X., Li, Y., Li, X., Tao, W., Li, B., Wang, Y., Yang, L., Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication. Integr. Biol.: Quant. Biosci. Nano Macro 5:2 (2013), 351–371.
37. Weng, C.-J., Yen, G.-C., The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis. Clin. Exp. Metastas. 27:5 (2010), 361–369.
38. Wuertz, K., Vo, N., Kletsas, D., Boos, N., Inflammatory and catabolic signalling in intervertebral discs: the roles of NF-kappaB and MAP kinases. Eur. Cells Mater. 23 (2012), 103–119 (discussion 119-120).
39. Xu, K., Liang, X., Gao, F., Zhong, J., Liu, J., Antimetastatic effect of ganoderic acid T in vitro through inhibition of cancer cell invasion. Process Biochem. 45:8 (2010), 1261–1267.
40. Yang, S., He, P., Wang, J., Schetter, A., Tang, W., Funamizu, N., Yanaga, K., Uwagawa, T., Satoskar, A.R., Gaedcke, J., Bernhardt, M., Ghadimi, B.M., Gaida, M.M., Bergmann, F., Werner, J., Ried, T., Hanna, N., Alexander, H.R., Hussain, S.P., A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2. Cancer Res. 76:13 (2016), 3838–3850.
41. Zhai, Y., Bommer, G.T., Feng, Y., Wiese, A.B., Fearon, E.R., Cho, K.R., Loss of estrogen receptor 1 enhances cervical cancer invasion. Am. J. Pathol. 177:2 (2010), 884–895.
42. Zhang, G., Zhao, C., Wang, Q., Gu, Y., Li, Z., Tao, P., Chen, J., Yin, S., Identification of HIF-1 signaling pathway in Pelteobagrus vachelli using RNA-Seq: effects of acute hypoxia and reoxygenation on oxygen sensors, respiratory metabolism, and hematology indices. J. Comp. Physiol. B, 2017.
43. Zhao, Q., Yue, J., Zhang, C., Gu, X., Chen, H., Xu, L., Inactivation of M2 AChR/NF-kappaB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC). Oncotarget 6:30 (2015), 29335–29346.
44. Zhao, R., Chen, M., Jiang, Z., Zhao, F., Xi, B., Zhang, X., Fu, H., Zhou, K., Platycodin-D induced autophagy in non-small cell lung cancer cells via PI3K/Akt/mTOR and MAPK signaling pathways. J. Cancer 6:7 (2015), 623–631.
45. Zhao, R.L., Yin, P.H., Ni, Z.H., Sun, J., Xu, K., He, Y.M., Efficacy evaluation of Chinese medicine-based treatment of pancreatic cancer. China J. Tradit. Chin. Med. Pharm., 32(3), 2017, 4.